Identification of biomarkers has the potential to facilitate major advancements in Alzheimer’s disease diagnosis and management. This symposium will present data on imaging targets for Alzheimer pathology, discuss quantitative analysis of longitudinal imaging data, and describe its clinical impact and utility. 

Clinical efficacy of memantine and acetylcholinesterase inhibitors as monotherapies for treatment of Alzheimer disease (AD) is well documented. Preclinical rationale and clinical evidence from large-scale, robustly designed studies make combined treatment with memantine and donepezil a natural option for the moderate stages of AD onwards. The treatment is supported by health economic analyses and acknowledged in many treatment guidelines worldwide.

International experts will discuss current needs in Alzheimer’s disease management, focusing on functional decline and its impact on the patient/caregiver. The scientific rationale for cholinesterase inhibition, including latest approaches to treatment with cholinesterase inhibitors, will be explored in the context of data from a recent clinical trial of rivastigmine patch.  

Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked in part by an accumulation of beta-amyloid, a product of aberrant proteolysis. In this Interactive Forum, the evidence supporting a pathogenic role for beta-amyloid will be explored across the spectrum of AD, from the preclinical phase through clinical dementia. Faculty will examine emerging insights into early diagnosis and amyloid-based disease-modifying strategies. 

The neurotrophic regulation is suppressed in Alzheimer’s disease. Current evidence indicates that a therapeutic intervention directed at the restoration of the lost neurotrophic balance may benefit AD patients.
The symposium covers state-of-the-art in the neurotrophic research and discusses the clinical application of multimodal interventions based on Cerebrolysin, a neurotrophic agent.

A distinguished panel of speakers will review and discuss various dimensions of a new nutritional approach in AD, including:

• Synapse loss in AD
• Nutrient status and metabolism in AD
• Early stage Alheimer's
• Results from the Souvenaid clinical trials program